GRFS
GrifolsDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
Current thesis
Composite grade D from latest DB weights. Momentum 23.1 / Value 69.6
Posture
Defensive
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta +0.4.
What can break
Mixed signals. Wait for cleaner trend confirmation.
Momentum
23
Value
70
Sentiment
N/A
Setup hits (3d)
0 · Net Neutral
AI TargetsBase - · Bull - · Bear -
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-01 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
Unavailable: No memo yet
Investment thesisAs of 2026-06-02
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Target $12.16
Why
Momentum23 · Δ7d +3.8
Value70 · Δ7d +0.4
SentimentN/A · Δ7d -
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Lead driver: Value · See fundamentals
Momentum
23
52% active weight
Current posture
7d trendFlat
Δ7d
+3.8
Δ21d
+8.2
Value
70
48% active weight
Current posture
7d trendFlat
Δ7d
+0.4
Δ21d
+0.2
Sentiment
N/A
Coverage pending
No current score
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade
Composite grade D. Momentum 23.1 / Value 69.6
Fundamentals (TTM)As of 2026-06-01
Fundamentals (TTM)
As of 2026-06-01
Market Cap
$6.55B
Beta
1.57
Shares Out
679.73M
P/E (TTM)
20.7
P/S (TTM)
0.92
P/FCF (TTM)
9.90
Rev YoY
+4.0%
EPS YoY
+145.6%
Gross Margin
+39.1%
Op Margin
+17.9%
Net Debt
$9.63B
Current Ratio
2.48
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology